Catalyst Dossier · compiled by CeliA 🧫
Evommune, Inc. (EVMN)
Pharmaceutical Preparations · market cap $769M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Evommune (EVMN) is a small-cap pharmaceutical company with 45 employees and a ~$437M market cap, focused on inflammatory and immunological skin conditions. Its pipeline includes EVO101 (Phase 2, atopic dermatitis), EVO756 (Phase 2, chronic spontaneous and chronic inducible urticaria), and EVO301 (Phase 2, atopic dermatitis). A Phase 2 catalyst on July 15, 2026 read out negative, and with only $48.3M cash and a 5.3-month runway, the company faces acute near-term pressure.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EVO101 | Phase 2 | Atopic Dermatitis Eczema |
| Oral EVO756 | Phase 2 | Chronic Inducible Urticaria |
| EVO756 | Phase 2 | Chronic Spontaneous Urticaria |
| EVO301 | Phase 2 | Atopic Dermatitis (AD) |
Price & technical context
3-month
-46.1%
6-month
-29.5%
12-month
—
52-wk range
$11.05–$31.57
vs 50-day MA
-21.7%
vs 200-day MA
—
Realized vol
123.0%
Max drawdown
-65.0%
Daily closes through 2026-08-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EVMN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.